Abingworth’s Cellectis CLLS Stock Holding History

Abingworth’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$1.66M	–	17
2018 Q4	$1.66M	Hold	100,000	–	–	1.51%	11
2018 Q3	$2.82M	Hold	100,000	–	–	1.68%	11
2018 Q2	$2.83M	Hold	100,000	–	–	1.61%	12
2018 Q1	$3.15M	Hold	100,000	–	–	1.96%	8
2017 Q4	$2.92M	Hold	100,000	–	–	2.11%	10
2017 Q3	$2.84M	Hold	100,000	–	–	1.97%	10
2017 Q2	$2.57M	Hold	100,000	–	–	2.04%	9
2017 Q1	$2.4M	Hold	100,000	–	–	1.79%	9
2016 Q4	$1.69M	Hold	100,000	–	–	1.41%	10
2016 Q3	$2.41M	Hold	100,000	–	–	2.31%	11
2016 Q2	$2.66M	Hold	100,000	–	–	2.78%	11
2016 Q1	$2.73M	Hold	100,000	–	–	2.54%	10
2015 Q4	$3.1M	Buy	+100,000	New	+$3.03M	1.87%	10

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Abingworth's CLLS Position: Q1 2019 in Review

Abingworth sold out of Cellectis (CLLS) in Q1 2019, closing a stake of 100,000 shares — an estimated $1.66M sold.

Abingworth first reported a position in CLLS in Q4 2015 and held it in 13 quarters. The position peaked at $3.15M in Q1 2018. 63 funds tracked by Wall St. Rank hold CLLS as of Q1 2019.

Abingworth reported no remaining Cellectis position as of Q1 2019 after selling out during the quarter.
Abingworth sold 100,000 Cellectis shares in Q1 2019, an estimated $1.66M.
Abingworth first reported a position in Cellectis in Q4 2015 and held it in 13 quarters.
Abingworth's Cellectis position peaked at $3.15M in Q1 2018.
63 funds tracked by Wall St. Rank held Cellectis as of Q1 2019.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.